Federal Register Notice: FDA has determined the regulatory review period for Genentech’s Perjeta (pertuzumab) is 3,925 days for extending a patent which claims the human biological product. Perjeta is indicated in combination with trastuzumab and docetaxel for treating patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. To view this notice, click here.
